Lineage Determination of CD20– B-Cell Neoplasms
نویسندگان
چکیده
منابع مشابه
Histiocytic/dendritic cell transformation of indolent B-cell neoplasms: Clinical laboratory evidence of lineage conversion in hematolymphoid malignancies
It is well known that pluripotent progenitors of normal hematopoietic cells can differentiate into cell lineages that are distinct in morphology, immunophenotype and biological function . The conventional concept holds that once a hematopoietic progenitor is committed to a given lineage, its fate is sealed and irreversible. This phenomenon of lineage commitment has also been universally observe...
متن کاملImmunohistochemical classification of B cell neoplasms.
Rapid responses http://jcp.bmj.com/cgi/eletter-submit/56/3/193 You can respond to this article at: service Email alerting top right corner of the article Receive free email alerts when new articles cite this article sign up in the box at the Topic collections (13598 articles) Immunology (including allergy) (1484 articles) Molecular genetics Articles on similar topics can be found in the f...
متن کاملCD20+ B cell depletion alters T cell homing.
Depleting mAbs against the pan B cell marker CD20 are remarkably effective in the treatment of autoimmune-mediated inflammatory disorders, but the underlying mechanisms are poorly defined. The primary objective of this study was to find a mechanistic explanation for the remarkable clinical effect of the anti-CD20 mAbs in a representative nonhuman primate autoimmune-mediated inflammatory disorde...
متن کاملCell lineage determination in the mouse.
During the peri-implantation development of the mouse embryo from the blastocyst through gastrulation, Pou5f1 (OCT-4) down-regulation is closely linked to the initial step of lineage allocation to extraembryonic and embryonic somatic tissues. Subsequently, differentiation of the lineage precursors is subject to inductive tissue interactions and intercellular signalling that regulate cell prolif...
متن کاملEfficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
The anti-CD20 antibody rituximab is useful in the treatment of certain B-cell malignancies, most notably non-Hodgkin's lymphoma. Its efficacy has been increased when used in combination with chemotherapy, yet anti-CD20 monoclonal antibodies (mAbs) directly conjugated with drugs such as doxorubicin (Dox) have failed to deliver drug or to demonstrate antitumor activity. We have produced anti-CD20...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Clinical Pathology
سال: 2006
ISSN: 0002-9173,1943-7722
DOI: 10.1309/3wg32yramq7rb9d4